Cite
HARVARD Citation
Loibl, S. et al. (n.d.). 122TiPGeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. Annals of oncology. p. . [Online].